The activity of the kinase inhibitor Gefitinib on CLL cells and stromal interactions.

激酶抑制剂吉非替尼对 CLL 细胞和基质相互作用的活性。

• 批准号: 252757
• 负责人: DeLong Rebecca F
• 金额: $ 1.27万
• 依托单位: Manitoba Institute of Cell Biology (Winnipeg)
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2012
• 资助国家: 加拿大
• 起止时间: 2012-02-01 至 2013-02-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=252757&lang=en
• 关键词: Cancer Research; Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults of the Western World. In the large majority of cases, this is a disease affecting B cells of the immune system. Various combinations of chemotherapeutic drugs exist for treatment of

慢性淋巴细胞白血病(CLL)是西方世界成年人最常见的白血病。在绝大多数病例中，这是一种影响免疫系统B细胞的疾病。目前有多种化疗药物组合用于治疗食道癌